Anupam Rasayan India Ltd. ANURAS
NSE · India · Health Technology
INR 1,163.70-17.30 (-1.46%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Anupam Rasayan India Ltd (BOM:543275) posts 36% revenue surge, commercializes a world-first flow chemistry product, and advances its transformative Bliss GVS Pharma acquisition.
Anupam Rasayan India Ltd (BOM:543275) reports a 26% increase in quarterly income and strategic moves to enhance its pharmaceutical platform.
Anupam Rasayan India Ltd (BOM:543275) reports a remarkable 149% revenue increase in Q2 FY26, with strategic advancements in product commercialization and working capital efficiency.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.